NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…
Month: September 2024
NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…
NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of ZoomInfo Technologies Inc. (“ZoomInfo” or the “Company”) (NASDAQ: ZI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…
NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of ZoomInfo Technologies Inc. (“ZoomInfo” or the “Company”) (NASDAQ: ZI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…
NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of DraftKings Inc. (“DraftKings” or the “Company”) (NASDAQ: DKNG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…
NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of DraftKings Inc. (“DraftKings” or the “Company”) (NASDAQ: DKNG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…
NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…
NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…
NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of AvidXchange Holdings, Inc. (“AvidXchange” or the “Company”) (NASDAQ: AVDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…
NEW YORK, Sept. 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of AvidXchange Holdings, Inc. (“AvidXchange” or the “Company”) (NASDAQ: AVDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The…